All In Biotech

Drug Trial Radar · NCT03874013

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

44

Actual

Start

Dec 7, 2017

Primary completion

Mar 6, 2020

Study completion Mar 6, 2020

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Mar 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Treatment of children with growth failure due to growth hormone deficiency (GHD). Primary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese pre-pubertal children with GHD. Secondary • To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of three different doses of MOD-4023 in Japanese pre-pubertal children with GHD.

Conditions

  • Growth Hormone Deficiency

Interventions

  • MOD-4023Drug

    MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN. MOD-4023 will be administered as a SC injection once weekly, using a delivery device.

  • GenotropinDrug

    Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections. A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated. Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Height Velocity (HV) After 12 MonthsTime frame: 12 months

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • Akita University Hospital

    Akita, Japan

  • Fukuoka Children's Hospital

    Fukuoka, Japan

  • Gifu University Hospital

    Gifu, Japan

  • Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Miyazaki Prefectural Miyazaki Hospital

    Miyazaki, Japan

  • Arakawa Children's Clinic

    Nagano, Japan

  • Nara Prefecture General Medical Center

    Nara, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Japan

  • Okayama Saiseikai General Hospital Outpatient Center

    Okayama, Japan

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan

  • Osaka City General Hospital

    Osaka, Japan

  • Osaka City University Hospital

    Osaka, Japan

  • Saitama Childrens Medical Center

    Saitama, Japan

  • Saitama City Hospital

    Saitama, Japan

  • Shizuoka Childrens Hospital

    Shizuoka, Japan

  • Toranomon Hospital

    Tokyo, Japan

  • Aichi Medical University Hospital

    Nagakute, Aichi-ken, Japan

  • Seirei Sakura Citizen Hospital

    Sakura, Chiba, Japan

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu, Fukuoka, Japan

  • Gunma University Hospital

    Maebashi, Gunma, Japan

  • Fukuyama City Hospital

    Fukuyama, Hiroshima, Japan

  • National Hospital Organization Kure Medical Center & Chugoku Cancer Center

    Kure, Hiroshima, Japan

  • Onomichi General Hospital

    Onomichi, Hiroshima, Japan

  • Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital

    Asahikawa, Hokkaido, Japan

  • Asahikawa Medical University Hospital

    Asahikawa, Hokkaido, Japan

  • KKR Sapporo Medical Center

    Sapporo, Hokkaido, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • Takahashi Clinic

    Kobe, Hyōgo, Japan

  • Takarazuka City Hospital

    Takarazuka, Hyōgo, Japan

  • St. Marianna University School of Medicine Hospital

    Kawasaki, Kanagawa, Japan

  • National Hospital Organization Minami Kyoto Hospital

    Jōyō, Kyoto, Japan

  • East Japan Railway Company Sendai Branch Office JR Sendai Hospital

    Sendai, Miyagi, Japan

  • National University Corporation Tohoku University Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Igarashi childrens clinic

    Sendai, Miyagi, Japan

  • Oita University Hospital

    Yufu, Oita Prefecture, Japan

  • Osaka Women's and Children's Hospital

    Izumi, Osaka, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Saitama Medical University Hospital

    Iruma-Gun, Saitama, Japan

  • Saitama Medical Center

    Kawagoe, Saitama, Japan

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.